Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Ann Neurol. 2015 Feb 9;77(3):399–414. doi: 10.1002/ana.24332

Figure 4. scAAV9-shSMN leads to SMA-like clinical symptoms in piglets.

Figure 4

(A) Time course of symptoms and progression of phenotype. (B) Recording set up for the measurement of the sciatic CMAP and MUNE responses. 1, recording electrodes E1 and E2; 2, anode and 3, cathode stimulating electrodes; 4, ground electrode. (C) Representative EMG recording from a control and a scAAV9-shSMN injected animal showing fibrillations with positive wave morphology. (D) CMAP and MUNE at PND54 were significantly reduced in scAAV9-shSMN animals (N=4) compared to the non-injected control group (N=6). The CMAP and MUNE values were preserved in the treated pre-symptomatic group that received scAAV9-shSMN and scAAV9-SMN vector 24hrs apart and the values were not significantly different from those of the unaffected controls. ** P<0.01